We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+1.86%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$54.7B
AUM Growth
+$1.45B
(+2.7%)
Cap. Flow
+$1.02B
Cap. Flow
% of AUM
1.86%
Top 10 Holdings %
Top 10 Hldgs %
17.33%
Holding
3,009
New
39
Increased
2,170
Reduced
725
Closed
55
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity National Information Services
FIS
|
+$65.3M |
| 2 |
Global Payments
GPN
|
+$40.3M |
| 3 |
Microsoft
MSFT
|
+$37.9M |
| 4 |
L3Harris
LHX
|
+$32.8M |
| 5 |
Amazon
AMZN
|
+$32.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
APC
Anadarko Petroleum
APC
|
+$64.3M |
| 2 |
RHT
Red Hat Inc
RHT
|
+$57.1M |
| 3 |
TSS
Total System Services, Inc.
TSS
|
+$40M |
| 4 |
WP
Worldpay, Inc.
WP
|
+$39.2M |
| 5 |
LLL
L3 Technologies, Inc.
LLL
|
+$32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.64% |
| 2 | Financials | 15.56% |
| 3 | Healthcare | 12.85% |
| 4 | Consumer Discretionary | 10.31% |
| 5 | Industrials | 10.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RYZ
2751
Ryerson Holding Corp
RYZ
$1.42B
| $195K | ﹤0.01% |
22,889
+171
| +0.8% | +$1.34K |
|
|
IIN
2752
DELISTED
IntriCon Corporation
IIN
| $195K | ﹤0.01% |
10,034
-75
| -0.7% | -$1.45K |
|
2753
Cytosorbents Corp
CTSO
$24.2M
| $194K | ﹤0.01% |
38,527
-300
| -0.8% | -$1.75K |
|
2754
Genco Shipping & Trading
GNK
$1.13B
| $193K | ﹤0.01% |
20,939
+2,297
| +12% | +$21.9K |
|
2755
Mizuho Financial
MFG
$131B
| $193K | ﹤0.01% |
62,834
+14,457
| +30% | +$43K |
|
|
GCAP
2756
DELISTED
Gain Capital Holdings, Inc.
GCAP
| $193K | ﹤0.01% |
36,641
+1,147
| +3% | +$5.36K |
|
|
PRTK
2757
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $192K | ﹤0.01% |
44,418
-300
| -0.7% | -$1.2K |
|
2758
OP Bancorp
OPBK
$234M
| $191K | ﹤0.01% |
19,560
+2,079
| +12% | +$19.9K |
|
|
FRTA
2759
DELISTED
Forterra, Inc
FRTA
| $191K | ﹤0.01% |
26,413
-369
| -1% | -$2.38K |
|
2760
Crinetics Pharmaceuticals
CRNX
$8.9B
| $190K | ﹤0.01% |
12,626
-125
| -1% | -$2.43K |
|
|
ADMS
2761
DELISTED
Adamas Pharmaceuticals
ADMS
| $190K | ﹤0.01% |
37,166
+2,974
| +9% | +$18.4K |
|
2762
Flotek Industries
FTK
$1.26B
| $189K | ﹤0.01% |
14,305
+1,231
| +9% | +$18.7K |
|
|
CBIO
2763
Crescent Biopharma
CBIO
$600M
| $189K | ﹤0.01% |
439
-4
| -0.9% | -$2.57K |
|
|
NAGE
2764
Niagen Bioscience
NAGE
$247M
| $188K | ﹤0.01% |
47,787
-15
| -0% | -$64 |
|
2765
Escalade
ESCA
$305M
| $187K | ﹤0.01% |
17,198
+1,547
| +10% | +$16.9K |
|
2766
Protagonist Therapeutics
PTGX
$8.77B
| $187K | ﹤0.01% |
15,540
+2,662
| +21% | +$33.5K |
|
2767
Ponce Financial Group
PDLB
$497M
| $185K | ﹤0.01% |
18,367
+1,444
| +9% | +$14.7K |
|
|
FFNW
2768
DELISTED
First Financial Northwest, Inc
FFNW
| $182K | ﹤0.01% |
12,302
+1,252
| +11% | +$17.9K |
|
|
CALA
2769
DELISTED
Calithera Biosciences, Inc
CALA
| $180K | ﹤0.01% |
2,921
+462
| +19% | +$37K |
|
2770
Sumitomo Mitsui Financial
SMFG
$162B
| $179K | ﹤0.01% |
26,188
+6,044
| +30% | +$41.3K |
|
|
DSKE
2771
DELISTED
Daseke, Inc. Common Stock
DSKE
| $178K | ﹤0.01% |
71,191
+7,071
| +11% | +$19.9K |
|
2772
Lineage Cell Therapeutics
LCTX
$279M
| $177K | ﹤0.01% |
180,201
+15,993
| +10% | +$16.6K |
|
2773
Lexicon Pharmaceuticals
LXRX
$1.08B
| $177K | ﹤0.01% |
58,748
-400
| -0.7% | -$1.24K |
|
2774
Clearfield
CLFD
$444M
| $176K | ﹤0.01% |
14,841
-125
| -0.8% | -$1.53K |
|
2775
Construction Partners
ROAD
$6.01B
| $175K | ﹤0.01% |
+11,245
| New | +$168K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2019 Portfolio in Review
As of Q3 2019, RhumbLine Advisers held 3,009 positions worth $54.7B, up 2.7% from $53.3B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Trading was light in Q3 2019: portfolio turnover was 3.1%. RhumbLine Advisers opened 39 new positions and exited 55, leaving the 3,009-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2019 buy was Avantor: 187,780 shares worth $2.76M.
- RhumbLine Advisers added most to Fidelity National Information Services in Q3 2019, an estimated $65.3M increase.
- RhumbLine Advisers's biggest Q3 2019 reduction was Leidos, cutting an estimated $15M.
- RhumbLine Advisers fully exited Anadarko Petroleum in Q3 2019, selling an estimated $64.3M.
- RhumbLine Advisers's ten largest holdings make up 17% of its $54.7B portfolio in Q3 2019.
- RhumbLine Advisers opened 39 new positions and closed 55 in Q3 2019.
- RhumbLine Advisers's portfolio value rose 2.7% quarter-over-quarter to $54.7B.
Based on RhumbLine Advisers's 13F filing for Q3 2019, filed 23 Oct 2019.